MRI study aims to unravel why some people feel dizzy after eating
NCT ID NCT07381816
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study uses MRI scans to measure blood flow in the gut after drinking sugar water in people with postprandial hypotension (a drop in blood pressure after meals) and healthy volunteers. Researchers will test whether blocking a hormone called GIP changes blood flow patterns. The goal is to better understand what causes this condition, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- GIP(3-30)NH2 infusion, hangrip exercises, saline infusion
- What this could lead to
- If successful, this could clarify how gut blood flow changes after eating in people with postprandial hypotension, potentially pointing toward new ways to manage the condition.
- What could go wrong
- This is a small, early-stage observational study with only 30 participants. It is not testing a treatment, so it may not lead directly to any therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOOD FLOW are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Glostrup hospital
Glostrup Municipality, 2600, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test